Periodontitis is among the most common chronic diseases worldwide and, along with caries, represents the leading cause of tooth loss. More recent theories regarding the etiology of periodontitis also attribute a significant role to the body's inflammatory response in the development and progression of the disease. It is already well established that periodontitis is bidirectionally associated with other systemic inflammatory conditions, such as type 2 diabetes mellitus. Results from meta-analyses suggest that diabetes increases the likelihood of periodontal disease by approximately 24%, while periodontitis, conversely, raises the risk of type 2 diabetes by about 26%. In addition to primary preventive measures and the modification of modifiable risk factors, diabetes mellitus is also treated pharmacologically with GLP-1 receptor agonists (GLP-1RA). In this context, Zhang et al. demonstrated that the administration of GLP-1RA, both in vitro and in vivo in rat models, leads to a significant reduction of pro-inflammatory substances in blood and periodontal tissue. However, to date, no clinical studies have investigated the effect of GLP-1RA on periodontal disease in humans. For this reason, the aim of this pilot study is to investigate the effect of GLP-1RA on the periodontal status of patients with periodontitis. The data from this pilot study will subsequently be used to perform a power analysis to determine the sample size for a double-blind, placebo-controlled clinical trial.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Effect of weekly GLP1-RA administration on periodontal clinical parameters (PD, CAL, BOP, furcation involvement, and tooth mobility) measured using a periodontal probe in patients with stage III or IV periodontitis.
Timeframe: From enrollment to the end of treatment at 16 weeks